KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Net Income (2016 - 2025)

Historic Net Income for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to -$27.1 million.

  • Neogenomics' Net Income fell 5327.98% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.5 million, marking a year-over-year decrease of 4598.09%. This contributed to the annual value of -$78.7 million for FY2024, which is 1050.61% up from last year.
  • Latest data reveals that Neogenomics reported Net Income of -$27.1 million as of Q3 2025, which was down 5327.98% from -$45.1 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Net Income ranged from a high of $75.9 million in Q2 2021 and a low of -$49.4 million during Q1 2022
  • Moreover, its 5-year median value for Net Income was -$24.3 million (2023), whereas its average is -$22.0 million.
  • Examining YoY changes over the last 5 years, Neogenomics' Net Income showed a top increase of 121185.52% in 2021 and a maximum decrease of 89577.63% in 2021.
  • Over the past 5 years, Neogenomics' Net Income (Quarter) stood at -$41.8 million in 2021, then soared by 45.67% to -$22.7 million in 2022, then surged by 36.85% to -$14.3 million in 2023, then dropped by 6.97% to -$15.3 million in 2024, then crashed by 77.04% to -$27.1 million in 2025.
  • Its Net Income was -$27.1 million in Q3 2025, compared to -$45.1 million in Q2 2025 and -$25.9 million in Q1 2025.